Medical/Pharmaceuticals
PharmAbcine to Participate in ACCESS CHINA Biotech Forum
DAEJEON, South Korea, Sept. 13, 2021 /PRNewswire/ -- PharmAbcine Inc. (KOSDAQ: 208340ks), a clinical-stage biotech company focusing on the development of next generation antibody therapeutics, announced today that the Company will virtually participate in ACCESSCHINA Biotech Forum. The event will...
2021-09-13 20:00
1734
I-Mab Added to FTSE ESG Index Series
SHANGHAI and GAITHERSBURG, Md., Sept. 13, 2021 /PRNewswire/ -- I-Mab (the "Company") (Nasdaq: IMAB), a clinical stage biopharmaceutical company committed to the discovery, development and commercialization of novel biologics, today announced that I-Mab will be added to the following FTSE ESG (Env...
2021-09-13 20:00
5064
Harbour BioMed Announces Phase I Study Positive Results on Next-Generation Anti-CTLA-4 Antibody HBM4003
CAMBRIDGE, Mass. and ROTTERDAM, Netherlands and SUZHOU, China, Sept. 13, 2021 /PRNewswire/ -- Harbour BioMed ("HBM", HKEX: 02142) announced positive results from its phase I dose escalation clinical trial of HBM4003 in solid tumors in Australia (the "phase I study"). The clinical data abstract has...
2021-09-13 14:34
3331
Samsung Biologics Joins Frontier 1.5D Project as part of 2050 Carbon Neutral Initiative
INCHEON, South Korea, Sept. 13, 2021 /PRNewswire/ -- Samsung Biologics (KRX: 207940.KS), the world's leading contract development and manufacturing organization, announced the signing of an MOU today to participate in the Frontier 1.5D initiative to develop a climate risk management model as part...
2021-09-13 12:41
2402
Kazia Therapeutics to Present at HC Wainwright 23rd Annual Global Investment Conference
SYDNEY, Sept. 10, 2021 /PRNewswire/ -- Kazia Therapeutics Limited (NASDAQ: KZIA; ASX: KZA), an oncology-focused drug development company, is pleased to announce that CEO, DrJames Garner, will be presenting at the HC Wainwright 23rd Annual Global Investment Conference, to be held virtually from13-...
2021-09-11 00:30
20749
Concord Medical Purchases Additional Proton Therapy System for It's Shanghai Concord Cancer Center
BEIJING, Sept. 10, 2021 /PRNewswire/ -- Concord Medical Services Holdings Limited ("Concord Medical" or the "Company") (NYSE: CCM), a healthcare provider specialized in cancer treatment, research, education, and prevention by establishing proton centers and specialty cancer hospitals and operatin...
2021-09-10 19:02
14755
Senhwa Announces First Patient Successfully Dosed in Phase 1b Expansion Study of Pidnarulex to Treat Solid Tumors with Specific Homologous Recombination Gene Mutations
TAIPEI and SAN DIEGO, Sept. 10, 2021 /PRNewswire/ -- Senhwa Biosciences, Inc. (TPEx: 6492), a drug development company focusing on first-in-class therapeutics for oncology, rare diseases, and novel coronaviruses, announced t hat their first patient has been successfully dosed, in a Phase1b c...
2021-09-10 19:00
15703
Yuyu Pharma Receives ISO 37001 Anti-Bribery Management System Certification
SEOUL, South Korea, Sept. 9, 2021 /PRNewswire/ -- Yuyu Pharma (KRX: 000220) received the ISO 37001 Anti-Bribery Management System (ABMS) certification from the British Standards Institution (BSI) inAugust 2021. Chief Executive Officer Robert Wonsang Yu said "we believe that the certification is a...
2021-09-09 21:00
3097
Medigate and CrowdStrike to Provide Healthcare Organizations with Unified Endpoint Security for Medical IoT Devices
Integration enables comprehensive visibility, enhanced risk management and security enforcement BROOKLYN, N.Y., Sept. 9, 2021 /PRNewswire/ -- Medigate, healthcare's Best in KLAS IoT Security Provider, today announced it has partnered with CrowdStrike, a leading provider of cloud-delivered e...
2021-09-09 20:51
2054
PharmAbcine Announces Joint Patent Application with MSD for the Treatment of Cancer
DAEJEON, South Korea, Sept. 9, 2021 /PRNewswire/ -- PharmAbcine Inc. (KOSDAQ: 208340ks), a clinical-stage biotech company focusing on the development of next-generation antibody therapeutics, today announced it submitted a Patent Cooperation Treaty (PCT) application for the combination therapy of...
2021-09-09 20:00
2217
China's Northernmost Free Trade Zone Sees Wider Reform and Opening-up
HARBIN, China, Sept. 9, 2021 /PRNewswire/ -- August 30 marks the second anniversary of the establishment of Harbin sub-area ofHeilongjiang pilot free trade zone (FTZ). Over the past two years, a total of 8,787 new enterprises have been established inHarbin sub-area. Nearly one-third of the enterp...
2021-09-09 18:06
2876
B dot Medical Successfully Develops Compact Scanning Magnet for Proton Cancer Therapy System
TOKYO, Sept. 9, 2021 /PRNewswire/ -- B dot Medical Inc. has conducted an energization test of the scanning magnet, which is designed and manufactured at its factory, for a compact proton cancer therapy system under development, and confirmed the generation of a magnetic field. That means a major ...
2021-09-09 15:00
1776
Biokangtai: Recombinant COVID-19 Vaccine(Adenovirus Vector) licensed for manufacturing, which actively promotes vaccine export and improves vaccine accessibility
SHENZHEN, China, Sept. 8, 2021 /PRNewswire/ -- The other day Shenzhen Kangtai Biological Products Co., Ltd. announced that the company and AstraZeneca signed the "Amendment 1 to License Agreement". In addition to authorizing BIOKANGTAI to commercialize its Recombinant COVID-19 Vaccine(Adenovirus ...
2021-09-09 11:40
4300
Kintor Pharma Announces the Primary Endpoint of Phase II Clinical Study for KX-826's Treatment of Androgenetic Alopecia Was Met
SUZHOU, China, Sept. 8, 2021 /PRNewswire/ -- Kintor Pharmaceutical Limited ("Kintor Pharma", HKEX:9939), a clinical-stage biotechnology company developing innovative small molecule and biological therapeutics, today announced the primary endpoint of phase II clinical trial of pyrilutamide ("KX-8...
2021-09-08 22:13
4764
The Valens Company Achieves Access to GMP Manufacturing in Australia & Expands International Footprint to Asia-Pacific through Exclusive Partnership with Epsilon Healthcare
Partnership will bring first GMP manufactured products to be sold through Valens in bothAustralia and New Zealand Access to Epsilon's GMP facility in Australia to provide Valens with future access to global markets includingLatin America, Europe, UK and Asia-Pacific KELOWNA, BC, Sept. 8, 2021 ...
2021-09-08 19:00
4188
Stem Cells for Everyone: I Peace expands its clinical-grade iPSC banking service leveraging mass manufacturing capability
PALO ALTO, Calif., Sept. 7, 2021 /PRNewswire/ -- I Peace, Inc. (CEO: Koji Tanabe , https://ipeace.com/), aPalo Alto-based biotech startup focusing on Nobel Prize-winning technology of induced pluripotent stem cells (iPSCs) expands its personalized iPSC banking service. I Peace launched its clinica...
2021-09-08 02:00
1902
Ethics Approval Granted for Clinical Trial of World's First Nasal Swab Designed Specifically for Children
* Rhinomed has created the world's first nasal swab designed specifically for children — The Rhinoswab Junior™ * Ethics approval has been received for a clinical trial to commence with the Murdoch Children's Research Institute (MCRI) at The Royal Children's Hospital in Melbourne * Trial seek...
2021-09-07 18:00
2753
Peijia Medical Engages Professor Saibal Kar as Exclusive Consultant
SUZHOU, China, Sept. 6, 2021 /PRNewswire/ -- Peijia Medical Limited (HKEX: 9996) is pleased to announceSaibal Kar MD, FACC, FSCAI, board-certified interventional cardiologist has agreed to become our exclusive consultant in China to advise the research and development of our Mitral Transcatheter E...
2021-09-06 13:44
4386
GeneQuantum and BrighGene sign agreement for development of antibody immune agonist conjugates
SUZHOU, China, Sept. 5, 2021 /PRNewswire/ -- GeneQuantum Healthcare (Suzhou) Co.,Ltd. (hereinafter referred to as "GeneQuantum") and BrighGene Biomedical (Suzhou) Co.,Ltd. (hereinafter referred to as "BrighGene ") signed a co-development agreement for antibody immune agonist conjugate (AIAC), GQ1...
2021-09-06 09:00
1851
AffaMed Therapeutics Enters into Strategic Partnership Agreement with Beijing Tiantan Hospital and Infinite Brain Technologies to Promote Digital Therapy in Neurological Diseases
BEIJING, Sept. 5, 2021 /PRNewswire/ -- AffaMed Therapeutics ("AffaMed"), a global clinical stage biopharmaceutical company dedicated to addressing critical unmet medical needs in ophthalmic, neurological and psychiatric disorders, announced during the recent "China International Trade in Servi...
2021-09-06 08:00
1695
Week's Top Stories
Most Reposted
Agoda Opens New Office at One Bangkok, Enhancing Its Technology Hub in Thailand
[Picked up by 321 media titles]
2026-04-09 13:00
Visa Opens the Door to AI-Driven Shopping for Businesses Worldwide
[Picked up by 312 media titles]
2026-04-09 09:00Tata Power Collaborates with Databricks to Build Future-Ready Data and AI Platform to Accelerate Energy Transition
[Picked up by 302 media titles]
2026-04-10 11:13
Hai Robotics and Maersk Redefine Fashion Fulfilment with High-Density Robotics at 10-Metre Scale in Singapore
[Picked up by 295 media titles]
2026-04-14 10:00
iQIYI to Open Its First Central China Theme Park in Wuhan, Continuing to Bring IP Value Beyond the Screen
[Picked up by 288 media titles]
2026-04-10 11:38
Most Read
Agoda Opens New Office at One Bangkok, Enhancing Its Technology Hub in Thailand
2026-04-09 13:00
8270
Visa Opens the Door to AI-Driven Shopping for Businesses Worldwide
2026-04-09 09:00
7778